Skip to main content
OpenTrials
Completed

NCT Number: NCT05382793

Assessment of the Daily Average Requirement of Iodine in Lactating Women

Human milk is the only source of iodine during early infancy and adequate iodine intake during lactation is necessary to assure optimal thyroid function in breastfed infants. However, the physiological requirement of iodine in lactating women is uncertain and recommendations for the daily dietary average requirement are poorly defined. WHO recommends iodine supplementation to lactating women in populations with incomplete coverage of iodized salt and deficient iodine intake, but the scientific evidence is weak and the optimal dose is uncertain.

The primary objective is to assess the daily dietary average requirement for iodine in lactating women.

Secondary objectives are to:

* Estimate the daily average requirement for iodine in exclusively breastfed infants; * Assess the dose-response of dietary iodine supplements on breast milk iodine concentration in lactating women with adequate and inadequate habitual iodine intakes; * Estimate the maternal iodine intake required to provide exclusively breastfed infants with an adequate iodine intake via breast milk.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–49 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Nutrition Research Unit, University Children's Hospital Zurich

Zurich, 8032, Switzerland

About this study

This study is a single center, randomized, controlled, dose-response metabolic balance study with cross-over design. The study will be conducted in 24 exclusively breastfeeding women and their infants receding in Zürich, Switzerland. The study involves an initial screening, a 2 weeks run-in period and a balance period over 3 weeks. Participating women will be allocated to two groups based on their consumption of dietary iodine supplements during pregnancy. Women who consumed daily iodine supplements during pregnancy will be assigned to group 1 (n=12) and receive daily supplements containing 150 µg iodine for 2 weeks, whereas women who did not will be enrolled in group 2 and will receive no supplement during the run-in period. Breast milk and spot urine samples (mothers and infants) will be collected daily in all participants during two weeks for the measurement of breast milk and urinary iodine concentrations. During the balance period, all women will receive either no supplement, iodine supplements providing 150 µg/day, or 300 µg/day in random order with cross-over design. Each supplement dose will be assessed in a test period of 7 days, including 2 run-in days, 3 balance days and 2 wash-out days. The supplements will be consumed during the first 5 days in each test-period. During the 3 balance days, the daily iodine intake and excretion will be measured in mothers and infants, and the iodine retention will be calculated for each regimen and study group. The minimum daily average requirement will be determined as the iodine intake where the iodine retention is zero.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Mother-infant pairs in good health, free of any acute illness or chronic thyroid disease.

Mothers

Inclusion criteria

  • Consent to enroll herself and her baby;
  • Age 18 to 49 years;
  • Singleton pregnancy;
  • Exclusively breastfeeding;
  • Self-estimated BMI <30 kg/m2 before conception.

Exclusion criteria

  • TSH >6 mIU/L;
  • Anemia (Hb <11.7 g/L);
  • Pregnancy (self-reported);
  • Acute illness (e.g. gastroenteritis);
  • History of thyroid disease, diabetes, metabolic disease or inflammatory bowel disease (self-reported);
  • Currently smoking (>1 cigarette/day);
  • Drug abuse or extensive alcohol intake;
  • Exposure to iodine-containing X-ray or computed tomography contrast agents during the past 6 months;
  • Adenomatous goiter, dermatitis, anti-C1q-vasculitis.

Infants

Inclusion criteria

  • Full term (38-42 weeks);
  • Birthweight ≥2.5 kg;
  • Exclusively breastfed;
  • Age 0-10 weeks at recruitment.

Exclusion criteria

  • Age >6 months;
  • TSH >10 mIU/L at neonatal screening at 2-5 days after birth (i.e. infants not requested to attend recall assessment);
  • Diagnosed or suspected colic.

Treatment and study plan

Control

Dietary Supplement

No iodine

Iodide (150 μg/day)

Dietary Supplement

A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide

Other names: Jodetten® 150 Henning, Sanofi-Aventis Germany GmbH, Germany

Iodine (300 μg/day)

Dietary Supplement

Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide

Other names: Jodetten® 150 Henning, Sanofi-Aventis Germany GmbH, Germany

Primary outcomes

  1. Maternal iodine retention (μg/day)

    Time frame: 24 hours

    Calculated as iodine intake (µg/day) minus the iodine excretion (µg/day)

Secondary outcomes

  1. Maternal iodine excretion in breast milk (μg/day)

    Time frame: 24 hours

    Estimated from measured breast milk iodine concentration (μg/L) and breast milk volume (L)

  2. Infant iodine retention (μg/day)

    Time frame: 24 hours

    Calculated as iodine intake (µg/day) minus the iodine excretion (µg/day)

Sponsors and collaborators

Lead sponsor

University Children's Hospital, Zurich

Other

Collaborators

  • ETH Zurich (Switzerland)

Registry information

Official study title

Assessment of the Daily Average Requirement of Iodine in Lactating Women: A Dose-response Metabolic Balance Study

Acronym: LISA

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
May 19, 2022
Registry last updated
Sep 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.